Ximerex Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

Ximerex General Information

Description

Provider of biotechnological research services. The company develops technology that provides cells, tissues, and organs from donor pigs for transplantation.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 2614 North 161st Avenue
  • Omaha, NE 68116
  • United States
+1 (402)
Primary Industry
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 2614 North 161st Avenue
  • Omaha, NE 68116
  • United States
+1 (402)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ximerex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 01-Dec-2022 Completed Startup
3. Grant 01-Jun-2013 Completed Startup
2. Grant 01-Jun-2005 $2.3M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Ximerex’s complete valuation and funding history, request access »

Ximerex Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • Pending

  • Expiring in next 12 mo

Ximerex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20090214482-A1 Transgenic mammals expressing human preproinsulin Inactive 13-Apr-2005
CA-2498711-C Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells Inactive 19-Sep-2002
AU-2003270728-B2 Growth of foreign cells in fetal animals facilitated by conditional and selective destruction of native host cells Inactive 19-Sep-2002
US-7626075-B2 Engrafting foreign replacement cells within fetal non-human mammal by selectively destroying native cells in tissue of fetal non-human mammal host, wherein number of maternal cells of same tissue is not substantially reduced; thereafter implanting foreign replacement cells in tissue of fetal mammal host Inactive 19-Sep-2002
US-20100075414-A1 Growth of foreign cells after conditional and selective destruction of fetal host cells Inactive 19-Sep-2002 C12N5/0081
To view Ximerex’s complete patent history, request access »

Ready to get started?

Request a free trial

Ximerex FAQs

  • When was Ximerex founded?

    Ximerex was founded in 1993.

  • Where is Ximerex headquartered?

    Ximerex is headquartered in Omaha, NE.

  • What industry is Ximerex in?

    Ximerex’s primary industry is Biotechnology.

  • Is Ximerex a private or public company?

    Ximerex is a Private company.

  • What is Ximerex’s current revenue?

    The current revenue for Ximerex is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »